Formation Bio Raises $372 Million in Series D Funding to Expand AI-Driven Pharma Capabilities and Acquire Candidate Drugs

Formation Bio raises $372M in Series D Funding

Formation Bio (Linkedin), a leading tech-driven pharma company, has secured an impressive $372 million in Series D funding. With a focus on AI and technology-enabled drug development, Formation Bio is poised to revolutionize the biotech and pharma industry.

Funding Amount: $372 million

Industry: Biotechnology Research

Employee Count: 51-200

CEO: Benjamine Liu (CEO Linkedin)

What Formation Bio needs to buy: Formation Bio is seeking partnerships with biotech and pharma companies that have candidate drugs ready for further development. Additionally, companies specializing in AI and technology solutions for drug development and clinical trials are ideal partners for Formation Bio. Together, they can advance drug programs, enhance development processes, and drive innovation in the industry.